HCPCS code J1940: Furosemide injection billing guide

Key Takeaways

HCPCS code J1940 described Injection, furosemide, up to 20 mg and was classified under Drugs Administered Other than Oral Method with a special coverage code of D

J1940 has been deleted from the active HCPCS code set; generic IV/IM furosemide injections should now be billed with J1938 (Injection, furosemide, 1 mg), while J1941 is reserved for the Furoscix branded subcutaneous product

CMS has identified J1940 as a single-dose container code, so JW and JZ wastage modifiers may be required on claims depending on whether drug residue is discarded or fully used

Pabau’s claims management software helps injection-based practices attach correct HCPCS codes and modifiers at the point of documentation, reducing furosemide billing errors

HCPCS code J1940 was the billing code for Injection, furosemide, up to 20 mg — the loop diuretic given by IV or IM injection for edema, heart failure, and related conditions. CMS deleted the code from the active HCPCS set, and any claim still using it is denied automatically.

For most generic furosemide injections, J1938 (Injection, furosemide, 1 mg) is now the code to use. J1941 is reserved specifically for the branded Furoscix subcutaneous product.

This guide covers the J1938 and J1941 replacement codes, JW/JZ modifier requirements, fee schedule context, related loop diuretic codes, and documentation standards for medical necessity, following the same injection billing best practices that apply across drug codes.

HCPCS code J1940: code description and properties

HCPCS code J1940 carried the official long descriptor: Injection, furosemide, up to 20 mg. The short descriptor used in most remittance systems was “Furosemide injection.” It sits within the J-code series of HCPCS Level II codes maintained by CMS, which covers drugs administered by routes other than oral (IV push, IV infusion, IM, subcutaneous, and similar).

Two code properties define how payers process J1940 claims. The HCPCS coverage code is D, meaning special coverage instructions apply. Billers cannot assume blanket Medicare coverage without verifying the applicable Local Coverage Determination (LCD) or National Coverage Determination (NCD) for the patient’s condition.

The action code recorded for this code was N, indicating no active maintenance, which preceded the formal deletion from the billable code set.

Furosemide itself is a loop diuretic approved by the FDA for treating edema associated with congestive heart failure, liver disease, and renal disease, as well as hypertension. Injectable furosemide is most commonly administered in acute or outpatient infusion settings when oral dosing is not feasible or effective.

Fee schedule and reimbursement for HCPCS code J1940

Because J1940 is deleted, it no longer appears on the active CMS Physician Fee Schedule. Reimbursement questions for generic furosemide should now be directed to J1938, or to J1941 for Furoscix claims specifically.

Understanding how J1940 was historically reimbursed still provides useful context for practices auditing old claims or appealing legacy denials.

Medicare Part B drug reimbursement for J-codes generally follows the Average Sales Price (ASP) methodology, set at ASP plus 6% for physician-administered drugs in outpatient settings. ASP rates are updated quarterly by CMS.

Medicaid and commercial payers may follow Average Wholesale Price (AWP) or contracted rates instead. Cross-reference any third-party dollar figures against the current CMS quarterly drug pricing file before using them for revenue projections.

Practices billing for IV therapy and injectable drug administration should configure their billing workflows around J1938 for standard furosemide claims, reserving J1941 for Furoscix specifically.

For practices managing multiple injectable drug codes, Pabau’s claims management software allows teams to map drugs to their correct HCPCS codes at the point of documentation, reducing the chance of submitting a deleted code on a live claim.

Buy-and-bill model considerations

Furosemide injection has historically been billed under the buy-and-bill model, where the provider purchases the drug and then bills the payer for both drug cost and administration. Under this model, the J-code on the claim represents the drug portion.

A separate administration code from the 96360-96379 series, such as 96365, covers the clinical act of administering the drug.

Submitting only the J-code without a corresponding administration code, or submitting the administration code without the drug J-code, creates a claim integrity problem. Both components belong on the same claim for the same date of service when the drug is purchased and administered by the provider.

Billing guidelines for furosemide injection claims

Billing furosemide injection correctly involves more than placing a code on a claim. The unit count, place of service, supporting diagnosis code, and modifier selection all affect whether the claim pays on first submission.

Unit billing

Unit billing works differently depending on which replacement code applies. For J1938, the standard crosswalk for generic IV or IM furosemide, each unit represents 1 mg. A 40 mg dose is billed as 40 units.

For J1941, used specifically for Furoscix, each unit still represents up to 20 mg, matching the original J1940 convention. Billing fractions of a unit is not supported for HCPCS J-codes, so round administered doses to the nearest whole unit under either code.

Place of service

Place of service (POS) affects reimbursement rates under Medicare. Outpatient hospital settings (POS 22) typically reimburse at a facility rate, while non-facility settings such as a physician office (POS 11) reimburse at the non-facility rate.

The difference can be material for high-cost drugs, though furosemide is a generic with low unit cost. Confirm the correct POS before claim submission to avoid rate discrepancies on remittance.

Diagnosis code linkage

Every drug claim requires a supporting ICD-10-CM diagnosis code that demonstrates medical necessity. For furosemide injection, appropriate diagnoses typically include edema, congestive heart failure, or hypertension. The diagnosis must be documented in the encounter note and match the ICD-10 code on the claim.

Mismatched diagnosis codes are among the most common reasons for J-code claim denials. Practices that document clinical encounters digitally with structured diagnosis fields reduce this mismatch rate considerably.

Teams handling mobile or outpatient infusion services benefit from using software that links diagnosis codes to administered drug codes at the time of charting. The same diagnosis-linkage discipline applies to other infused or injected drugs, such as J9202.

Detailed clinical notes must accompany the claim for any drug with coverage code D. The digital intake and clinical documentation tools your team uses should capture the treating diagnosis, the route of administration, the dose administered, and the supervising practitioner. Without this documentation in the patient record, a payer audit creates significant recoupment exposure.

Stop submitting claims with outdated codes

Pabau's claims management tools help injection-based practices attach the right HCPCS codes, wastage modifiers, and diagnosis linkages at the point of documentation. Fewer denials. Less rework. Book a demo to see it in action.

Book a demo

JW and JZ wastage modifiers: What billers must know

CMS identified J1940 as a code associated with single-dose containers, which means the JW and JZ modifier policy applies. Refund calculations for discarded amounts from single-dose containers began January 1, 2023, under CMS Change Request 13056 (Transmittal 12067).

Mandatory JZ modifier reporting took effect July 1, 2023, requiring providers to report one of two wastage modifiers on every claim involving a drug packaged in a single-dose container. Claims-editing enforcement of this requirement began in October 2023.

The policy addresses a common workflow scenario: A single-dose vial of furosemide may contain more drug than the prescriber orders. Whatever remains after administration must be discarded. The modifier tells the payer what happened to the unused portion.

For a practical example: A provider orders 10 mg of furosemide from a 20 mg single-dose vial. One billing unit (up to 20 mg) is submitted for the administered dose.

Because 10 mg was discarded, the biller also submits a separate JW line for the wasted portion. Medicare pays for the administered dose at the applicable rate; the JW line documents wastage but does not generate additional payment.

If the full 20 mg was administered, the provider appends JZ to the single claim line. This signals to the payer that no wastage occurred and no separate wastage line is needed.

Omitting both JW and JZ from a single-dose container claim, or applying them incorrectly, can trigger a claim edit or denial under NCCI (National Correct Coding Initiative) edits. Practices handling infusion or IV hydration services with multiple single-dose drug codes should build modifier selection into their billing workflow rather than relying on post-submission correction.

Related loop diuretic codes and the J1938 crosswalk

J1940’s deletion created a crosswalk that coders need to get right. Two codes replace it: J1938 for standard generic furosemide, and J1941 for the branded Furoscix product. Confusing the two can look like upcoding or undercoding to an auditor.

J1940, J1938, and J1941: What changed

J1941 describes “Injection, furosemide (furoscix), 20 mg.” The parenthetical “(furoscix)” reflects the branded subcutaneous formulation of furosemide approved by the FDA for outpatient use. Furoscix is a pH-neutral formulation designed for self-administered subcutaneous infusion using an on-body infusor patch, specifically for patients with chronic heart failure.

This distinction matters for billers. J1940 covered traditional intravenous or intramuscular furosemide injection in a practice or outpatient setting. That use case now maps to J1938 (Injection, furosemide, 1 mg), billed at 1 unit per mg administered, so a 40 mg dose is billed as 40 units.

J1941 covers the Furoscix product specifically and should only be used when that branded subcutaneous formulation is what was actually administered. Verify the furosemide product administered, and check with the AAPC Codify HCPCS code lookup and your payer’s drug billing policy, before assuming either code is the automatic replacement for a legacy J1940 claim.

Related HCPCS codes in the loop diuretic family

When reviewing a patient’s medication profile or preparing for an audit, billers may encounter adjacent codes in the J1-series, such as J1750 or J0690. The table below shows codes near J1940 for context. Verify currency of all codes before use, as HCPCS codes are updated quarterly and annually.

For practices with a broader injectable drug formulary, such as those also billing J2323 or other infusion drugs, the PGM Billing HCPCS lookup tool provides free access to CMS HCPCS Level II code data, including deletion status and descriptor text, which can be cross-referenced when auditing legacy claims.

Practices managing a range of IV and injectable therapy services will find a systematic approach to HCPCS code mapping saves significant time when payer audits arrive.

Practices offering IV therapy services should audit their charge master or fee schedule annually. Deleted HCPCS codes, and adjacent ones like S5000, need to be swapped for active codes before the next billing cycle.

A deleted code sitting in your charge master generates a denial every time it’s submitted, and those denials often go unnoticed until the claim ages past the timely filing limit.

Using prescription management software that flags drug-to-code mapping against the current HCPCS code file reduces this risk at the source.

Conclusion

Furosemide injection billing was already complex before J1940’s deletion. Now, with J1938 and J1941 splitting the replacement coding and mandatory JW/JZ modifier requirements for single-dose containers, getting the claim right demands attention to code currency, unit counting, diagnosis linkage, and documentation depth.

Pabau’s claims management software helps injection-based practices build these billing rules into the documentation workflow, so coders work with validated code-drug mappings and modifier prompts before a claim reaches the clearinghouse.

For practices that want the broader context, our guide to medical billing covers the fundamentals behind these code-specific workflows. To see how Pabau handles HCPCS code management from documentation through claim submission, book a demo.

Continue your research

Running an IV therapy or infusion practice? IV therapy EMR software covers the documentation, scheduling, and billing features injection-based practices need.

Need a cleaner intake process for injectable drug services? IV therapy intake template walks through the clinical and consent fields that support medical necessity documentation.

Want to reduce compliance risk across your practice? Medical spa compliance checklist covers the documentation and workflow standards that apply to injection-based services.

Frequently asked questions